IONIS-MAPTRx

IONIS-MAPTRx (BIIB080) is the first Tau-lowering antisense oligonucleotide (ASO) . IONIS-MAPTRx has the potential for the research of Alzheimer Disease[1].

Product Specifications

CAS Number

[2857842-32-9]

Product Name Alternative

BIIB080; ISIS 814907

UNSPSC

12352208

Target

Tau Protein

Type

Oligonucleotides

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/ionis-maptrx.html

Purity

92.31

Solubility

H2O : 100 mg/mL (ultrasonic)

Smiles

[IONIS-MAPTRx]

Molecular Weight

6430.39

References & Citations

[1]Laurence Mignon, et al. Design of the First-in-Human Study of IONIS-MAPTRx, a Tau-lowering Antisense Oligonucleotide, in Patients With Alzheimer Disease (S2.006) . Neurology Apr 2018, 90 (15 Supplement) S2.006.|[2]Rationale for and Development of IONIS-MAPTRx, the First Tau-lowering Antisense Oligonucleotide, in Patients with Mild AD|[3]DeVos SL, Miller RL, Schoch KM, et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med. 2017;9 (374) :eaag0481. |[4]Methods for reducing tau expression. WO2023004390A1